On July 9, 2026, Dr. Kimura, Founder & CEO of Bloom X³, gave a guest lecture at the open seminar “Introduction to Medical Business & Innovation,” hosted by the Department of Management of Intellectual Property, Kyoto University Graduate School of Medicine (School of Public Health). Held as a joint seminar with Kagoshima University School of Medicine, it took place in hybrid format at Kyoto University’s Medical Innovation Center and online. A large number of students and staff from both universities attended, as the lecture unpacked the essence of the U.S. drug-discovery ecosystem model and the challenges facing Japan’s life sciences.
Topic: The Reality of U.S. Biotech Ventures — the Soil Where New Therapeutics Are Born
Starting from the question, “Why doesn’t good medical research automatically become a good drug?”, the lecture argued that the difference lies not in the science itself but in the operational architecture that translates research into medical and business value — a perspective offered to the next generation of researchers and clinicians.
Dr. Kimura has worked across pharmaceutical R&D and business development in Japan, the U.S. and Europe, U.S. biotech venture investing, and academia, contributing to the creation of several global medicines. Drawing on that experience, he spoke concretely about what actually happens in the gap between research and business.
Themes explored
The session offered perspectives relevant to those working across pharma, biotech, academia, investment and consulting.
- Why does excellent medical research so often fail to become a drug — or a business?
- What is the “operational architecture” behind the U.S.’s enduring lead in creating new medicines?
- A perspective for translating research into medical value, business value — and careers
- Designing the drug-discovery ecosystem that connects academia, biotech, investment and pharma
- The essential challenges Japan’s life sciences should address next
Above all, drawing on experience built through close engagement with the field’s global top players, the talk unpacked how U.S. biotech investment and the drug-discovery ecosystem have been built — and the points that truly matter in how the United States came to construct them.
Bloom X³ will continue to return practical know-how — connecting science, business, capital and talent — to academia and society. For lectures, discussions or collaborations on these themes, please feel free to get in touch.
We extend our sincere thanks to everyone at Kyoto University Graduate School of Medicine and Kagoshima University School of Medicine for this valuable opportunity.
